Accelerating the Hit-To-Lead Optimization of a SARS-CoV-2 Mpro Inhibitor Series by Combining High-Throughput Medicinal Chemistry and Computational Simulations

In this study, we performed the hit-to-lead optimization of a SARS-CoV-2 Mpro diazepane hit (identified by computational methods in a previous work) by combining computational simulations with high-throughput medicinal chemistry (HTMC). Leveraging the 3D structural information of Mpro, we refined th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry Vol. 68; no. 8; pp. 8269 - 8294
Main Authors: Hazemann, Julien, Kimmerlin, Thierry, Mac Sweeney, Aengus, Bourquin, Geoffroy, Lange, Roland, Ritz, Daniel, Richard-Bildstein, Sylvia, Regeon, Sylvain, Czodrowski, Paul
Format: Journal Article
Language:English
Published: WASHINGTON Amer Chemical Soc 24.04.2025
Subjects:
ISSN:0022-2623, 1520-4804, 1520-4804
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we performed the hit-to-lead optimization of a SARS-CoV-2 Mpro diazepane hit (identified by computational methods in a previous work) by combining computational simulations with high-throughput medicinal chemistry (HTMC). Leveraging the 3D structural information of Mpro, we refined the original hit by targeting the S1 and S2 binding pockets of the protein. Additionally, we identified a novel exit vector pointing toward the S1 ' pocket, which significantly enhanced the binding affinity. This strategy enabled us to transform, rapidly with a limited number of compounds synthesized, a 14 mu M hit into a potent 16 nM lead compound, for which key pharmacological properties were subsequently evaluated. This result demonstrated that combining computational technologies such as machine learning, molecular docking, and molecular dynamics simulation with HTMC can efficiently accelerate hit identification and subsequent lead generation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
1520-4804
DOI:10.1021/acs.jmedchem.4c02941